Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $20.40

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.40.

Several equities analysts have recently weighed in on KROS shares. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Wells Fargo & Company reduced their price target on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Finally, Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $10.41 on Friday. The stock has a market cap of $206.01 million, a PE ratio of -3.46 and a beta of 0.94. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The stock has a fifty day moving average of $11.00 and a 200-day moving average of $14.42.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. On average, sell-side analysts predict that Keros Therapeutics will post -5.19 EPS for the current year.

Insider Activity

In related news, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. This represents a 19.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 8,425 shares of company stock worth $89,995. 20.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Keros Therapeutics

Large investors have recently added to or reduced their stakes in the business. Financial Management Professionals Inc. bought a new stake in Keros Therapeutics during the fourth quarter valued at $29,000. Caitong International Asset Management Co. Ltd boosted its stake in Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares during the period. Tower Research Capital LLC TRC boosted its stake in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the period. XTX Topco Ltd bought a new stake in Keros Therapeutics during the fourth quarter valued at $212,000. Finally, New York State Common Retirement Fund boosted its stake in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after buying an additional 7,700 shares during the period. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.